1. National Institutes of Health. COVID-19 treatment guidelines: ritonavir-boosted nirmatrelvir (paxlovid), https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir%5fpaxlovid-/. Accessed September 2, 2022.
2. Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine kinase inhibitors. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK563322/?report=classic. Accessed September 2, 2022.
3. NCCN. Non-small cell lung cancer, Version 4. 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed September 3, 2022.
4. Food and Drug Administration. VIZIMPRO® (dacomitinib) FDA package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf. Accessed
5. Food and Drug Administration. LORBRENA® (lorlatinib) FDA package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf. Accessed 02 September 2, 2022.